Shares of NeoGenomics surged 10.2% to $19.14 after the company announced that Medicare will now pay for its blood-based cancer-monitoring test to track how late-stage tumor patients respond to immunotherapy drugs — a fast-growing class of treatments used in lung cancer, melanoma, bladder cancer, and more. The question for investors: does a third government reimbursement stamp turn NeoGenomics into a real growth story, or merely keep it in the hunt against larger rivals?
• Medicare Now Covers Three Uses, With Two More Pending. This is the third Medicare-covered use for the company's molecular residual disease test, which already covers certain head-and-neck and breast cancers.
NeoGenomics also has two additional submissions pending with Medicare's review program. Each new approval removes a billing barrier for oncologists who might otherwise skip a test costing thousands of dollars, directly expanding the pool of patients whose tests get reimbursed.
• Immunotherapy Monitoring Opens a Massive Patient Pool. Immunotherapy is reshaping solid tumor treatment, and clinicians increasingly want dynamic tools to evaluate how patients respond over time.
The global MRD testing market reached an estimated $2.77 billion in 2026 and is projected to exceed $7.7 billion by 2035. Covering immunotherapy response monitoring — where patients may need repeated blood draws over months or years — could turn a one-time test into a recurring revenue stream per patient.
• The Stock Is Bumping Against What Analysts Think It's Worth. At $19.14, NeoGenomics now trades near the consensus analyst price target of roughly $19.72.
The company posted Q2 revenue of $201.7 million, returned to a small quarterly profit, and raised its full-year 2026 revenue outlook to $802–$806 million — up from approximately $727 million in 2025. The surge still leaves the company projecting a full-year net loss of $34–$42 million, meaning profitability remains aspirational.
• Natera and Guardant Already Have a Head Start. Natera's competing test is already covered by Medicare for colorectal, bladder, breast, and ovarian cancers, and its broad pan-cancer version monitors immunotherapy response across tumor types.
Guardant's tissue-free alternative targets colorectal and solid tumors with a simpler workflow. NeoGenomics is playing catch-up on coverage breadth, and reimbursement alone doesn't guarantee physician adoption.
The bottom line: Medicare validation is genuinely meaningful — but with the stock now trading near consensus fair value and bigger competitors already entrenched, investors need to see these new indications convert into volume growth before the rally earns its keep.